Infectious Complications Following CD19 CAR T Cell Immunotherapy for Children and Young Adults with Refractory ALL
Surabhi B Vora(University of Washington), Rebecca Gardner(Seattle Children's Hospital), Joshua A. Hill(Seattle Pacific University), Alpana Waghmare(Seattle Children's Hospital), Janet A. Englund(Seattle Children's Hospital)
Cited by 7
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
|Blood|2017|564
CD19 CAR T cell product and disease attributes predict leukemia remission durability
|Journal of Clinical Investigation|2019|355
Extrathymic T Cell Deletion and Allogeneic Stem Cell Engraftment Induced with Costimulatory Blockade Is Followed by Central T Cell Tolerance
|The Journal of Experimental Medicine|1998|340